Across its top 20 institutional holders, LGND's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 21/100).

Quarterly Activity

Recent Activity

+$2.3B

Total Buy Value

$1.5B

Total Sell Value

New buy51

Trim114

Add134

Sold out43

185

Net Buyers

157

Net Sellers

Smart Money Convergence

LGND does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

Filings (90d)

$3.16M

Total Est. Value

10K shares

Planned Shares

Last Filed 2026-07-01

Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
ANDREW REARDON	Officer	2026-07-01	10K shares	$3.16M

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-14

2026-07-14

Ligand Pharmaceuticals completed its merger with XOMA Royalty Corporation on July 14, 2026, making XOMA Royalty a wholly owned subsidiary through a holding company reorganization. In connection with the closing, Ligand entered into an amended credit agreement with Citibank for a $125 million revolving credit facility maturing in September 2028. The loan includes covenants requiring a senior secured net leverage ratio of no more than 2.5x and minimum consolidated EBITDA of $100 million over the next four quarters, stepping up to $150 million after June 2027.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

53220K504

FAQ

Who are the top institutional investors holding LIGAND PHARMACEUTICALS (LGND)?

Major stakeholders currently include BlackRock, Inc. ($591.3M), Vanguard Portfolio Management LLC ($219.7M), Janus Henderson Group PLC ($201.6M). Based on the latest 13F filings, there are a total of 355 tracked investment funds and institutions maintaining positions in LGND.

What is the overall institutional sentiment toward LGND recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $277.8M, driven by 185 managers accumulating shares while 157 reduced their exposure.

Which institutions have been selling or reducing their LGND positions?

In the latest period, 114 funds trimmed their holdings, and 43 managers completely exited their positions. The aggregate reported sell value was $1.5B.

Are there any notable investors adding LGND to their portfolios?

Yes, buying activity remains notable. 51 institutions opened new positions in {ticker}, and 134 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.3B.